No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND
The current study found no clear evidence linking eltrombopag treatment and risk for cataract development/progression in patients with chronic immune thrombocytopenia (ITP).
The current post-hoc subanalysis of a phase 4 open-label study concluded that the effects on platelet counts after eltrombopag treatment for >2 years was comparable between the persistent immune thrombocytopenia (ITP) and the chronic ITP cohorts, with similar safety profiles.
These study results showed that heavily pretreated patients with persistent/chronic immune thrombocytopenia (ITP) who achieved a stable response with fostamatinib therapy maintained their responses for ≥12 months.
Results of this randomized, placebo-controlled phase 3 trial showed that avatrombopag was superior to placebo in terms of the cumulative number of weeks with a platelet response, platelet response at day 8, and durability of platelet response in patients with refractory chronic immune thrombocytopenia (ITP).
This open-label study reported that the majority of children with immune thrombocytopenia (ITP) who received open-label romiplostim for ≥6 months achieved a platelet response, with median platelet counts >50 × 109/L from week 12 onward and no new safety signals observed during the study period.
Leslie Lauersdorf insist that it's vital to inform your patients about what's involved in beginning daratumumab treatments, especially because of the lengthy chair time.
Tiffany Richards insists on the importance of survivorship care in patients with multiple myeloma and explains how to make sure patients stay as healthy as possible for as long as possible.
Tiffany Richards is excited about all the new multiple myeloma treatments that are being introduced, but understands that the question of how to best utilize these drugs still remains to be answered.
Tiffany Richards stresses the importance of educating patients about side effects and what to do when these side effects begin to present.
Tiffany Richards shares anecdotes that illustrate why it's important to really know your patients in order to effectively care for them.
Page 1 of 11
Results 1 - 10 of 106
Results 1 - 10 of 106